Melanotan 2: Mechanism, Research, Risks & Scientific Overview

Key Points

• Melanotan II is a synthetic analog of alpha-melanocyte-stimulating hormone (alpha-MSH)
• Acts primarily through melanocortin-1 receptor (MC1R) activation to stimulate melanogenesis
• NOT APPROVED by the FDA, EMA, TGA, or any regulatory agency worldwide for human use
• SIGNIFICANT SAFETY CONCERNS: Associated with changes to existing moles (nevi), potential melanoma risk, and cardiovascular effects
• Research is limited primarily to animal models and case reports of adverse events
• Classified as an unregulated research compound with substantial documented risks

Table of Contents

1. Introduction
2. Molecular Structure
3. Mechanism of Action
4. Research Overview
5. Safety Concerns & Adverse Effects
6. Regulatory Status
7. Difference from Melanotan I
8. Research Limitations
9. Conclusion
10. References

Introduction

Melanotan II (MT-II or MT-2) is a synthetic cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (alpha-MSH). Originally developed at the University of Arizona in the 1990s as a potential preventive agent against skin cancer through tanning without UV exposure, the compound was ultimately abandoned by mainstream pharmaceutical development due to significant safety concerns and unpredictable effects.

The peptide was designed to stimulate melanogenesis—the biological process by which melanin pigment is produced in the skin—without requiring ultraviolet radiation exposure. While this mechanism has been documented in research settings, the compound's non-selective activity at multiple melanocortin receptor subtypes has resulted in a complex profile of effects that extends far beyond skin pigmentation.

This article provides an objective scientific overview of Melanotan II, with particular emphasis on the documented safety concerns that have prevented its approval by any regulatory authority worldwide. Understanding these risks is essential for anyone reviewing the scientific literature on this compound.

Molecular Structure

Chemical Properties

Structural Characteristics

Melanotan II differs significantly from native alpha-MSH in several ways:

1. Cyclic Structure: MT-II contains a lactam bridge between the aspartic acid and lysine residues, creating a conformationally constrained ring structure that increases receptor binding affinity and metabolic stability.

2. Norleucine Substitution: The N-terminal methionine found in natural MSH is replaced with norleucine (Nle), preventing oxidative degradation.

3. D-Phenylalanine: Incorporation of the D-isomer of phenylalanine rather than the natural L-isomer enhances proteolytic resistance and alters receptor selectivity.

4. Acetylated N-terminus: The acetyl cap protects against aminopeptidase degradation.

5. Amidated C-terminus: The C-terminal amide group provides protection against carboxypeptidases.

These modifications result in a peptide with significantly greater potency and longer half-life compared to endogenous alpha-MSH, but also with altered receptor selectivity that contributes to its concerning side effect profile.

Mechanism of Action

Melanocortin Receptor System

Melanotan II exerts its effects through the melanocortin receptor (MCR) family, a group of five G protein-coupled receptors (MC1R through MC5R) with diverse physiological functions:

Unlike the more selective Melanotan I (afamelanotide), Melanotan II demonstrates significant agonist activity at MC1R, MC3R, MC4R, and MC5R. This non-selectivity is responsible for both its tanning effects and many of its adverse effects.

MC1R Activation and Melanogenesis

The primary mechanism for skin pigmentation involves MC1R activation on melanocytes:

1. Receptor Binding: MT-II binds to MC1R on epidermal melanocytes with high affinity
2. cAMP Cascade: Receptor activation stimulates adenylyl cyclase, increasing intracellular cyclic AMP (cAMP)
3. CREB Activation: Elevated cAMP activates protein kinase A (PKA), which phosphorylates CREB transcription factor
4. MITF Expression: CREB activation upregulates MITF (microphthalmia-associated transcription factor), the master regulator of melanocyte function
5. Melanogenic Enzymes: MITF increases expression of tyrosinase, TRP-1, and TRP-2—enzymes essential for melanin synthesis
6. Eumelanin Production: The net effect is increased production of eumelanin (brown-black pigment) within melanosomes
7. Pigment Transfer: Melanin-containing melanosomes are transferred to surrounding keratinocytes

This process occurs without UV exposure, distinguishing it from natural tanning responses that require DNA damage signals to initiate melanogenesis.

MC4R Effects (Central Nervous System)

MC4R activation by MT-II produces significant central nervous system effects:

• Sexual Function: MC4R in the hypothalamus mediates erectile responses in males and sexual arousal in females. This effect led to the development of bremelanotide, a related compound, for hypoactive sexual desire disorder.
• Appetite Suppression: MC4R activation in hypothalamic nuclei reduces food intake and increases energy expenditure
• Cardiovascular Effects: Central MC4R activation can increase heart rate and blood pressure through sympathetic nervous system modulation

MC3R Effects

MC3R activation contributes to:

• Cardiovascular regulation
• Inflammatory modulation
• Energy homeostasis effects

Research Overview

Early Development History

Melanotan II was synthesized at the University of Arizona by researchers seeking to develop a photoprotective agent. The rationale was that inducing melanogenesis without UV exposure could protect fair-skinned individuals from UV-induced skin damage and potentially reduce melanoma risk through increased epidermal melanin.

Early pharmacological studies characterized the peptide's receptor binding profile and demonstrated its ability to induce melanogenesis in cell culture and animal models (Hadley et al., 1989; Dorr et al., 1996). However, the compound's non-selective receptor activity quickly revealed a complex pharmacological profile extending beyond simple tanning effects.

Animal Studies

Preclinical research documented several effects:

Pigmentation Studies

• Increased melanin content in rodent skin without UV exposure
• Dose-dependent darkening observed in multiple species
• Effects persisted for extended periods after discontinuation

Behavioral Studies

• Sexual behavior changes in rodent models through MC4R activation
• Yawning and stretching behaviors (classical melanocortin effects)
• Appetite suppression documented in feeding studies

Cardiovascular Effects

• Blood pressure elevation observed in animal models
• Heart rate increases documented with acute administration
• Concerns raised about cardiac safety profile

Human Case Reports and Observational Data

The majority of human data on Melanotan II comes from case reports of adverse events, surveillance studies of illicit use, and small observational studies. Formal clinical trials were largely discontinued due to safety concerns.

Documented Observations:

• Skin darkening effects confirmed in uncontrolled observations
• Frequent nausea and facial flushing reported
• Changes in existing melanocytic nevi (moles) documented in multiple reports
• New nevus development observed
• Sexual effects reported consistent with MC4R activation
• Cardiovascular symptoms including palpitations and hypertension reported

Safety Concerns & Adverse Effects

CRITICAL SAFETY WARNING

Melanotan II has NOT been approved by any regulatory agency for human use. The following safety concerns have been documented in the scientific literature and represent significant reasons for this lack of approval.

Melanoma and Skin Cancer Concerns

The most serious documented concern involves Melanotan II's potential relationship to melanoma development and changes in existing moles:

Nevus Changes: Multiple case reports have documented significant changes in melanocytic nevi (moles) following MT-II use:

• Increased size and darkening of existing moles (Langan et al., 2009)
• Development of new melanocytic lesions (Hjuler & Lorentzen, 2014)
• Atypical dermoscopic features emerging in previously benign nevi
• Changes meeting clinical criteria for concerning lesions requiring excision

Melanoma Case Reports: Several case reports have documented melanoma diagnoses in individuals using MT-II:

• Reid et al. (2013) reported a case of melanoma in situ arising in a MT-II user
• Paurobally et al. (2012) documented melanoma development associated with MT-II use
• Multiple surveillance studies have reported melanoma cases among MT-II users

Mechanism of Concern: The theoretical basis for melanoma concern involves:

1. Proliferative Stimulation: MC1R activation promotes melanocyte proliferation, potentially affecting cells with pre-existing mutations
2. Masking Effect: Darkened skin may mask early melanoma detection
3. Nevus Activation: Stimulation of dormant or atypical melanocytes within existing nevi
4. Bypassing Protective Mechanisms: Natural tanning involves p53-mediated responses that may have tumor-suppressive functions; MT-II bypasses these pathways

Important Note: While a direct causal relationship between MT-II and melanoma has not been definitively established in controlled trials, the biological plausibility combined with multiple case reports has led regulatory agencies and medical organizations to issue warnings against its use.

Cardiovascular Effects

Melanotan II has documented cardiovascular effects that represent significant safety concerns:

• Hypertension: Blood pressure elevation documented in case reports and consistent with MC3R/MC4R activation of sympathetic tone
• Tachycardia: Increased heart rate reported as common side effect
• Palpitations: Cardiac awareness and irregular rhythms reported
• Flushing: Vasomotor instability particularly following injection

Individuals with pre-existing cardiovascular conditions face elevated risk from these effects.

Gastrointestinal Effects

Nausea is among the most commonly reported adverse effects:

• Nausea reported in majority of users in observational surveys
• Facial flushing often accompanies nausea
• Fatigue and general malaise reported
• Appetite suppression (related to MC4R activation)

Other Documented Adverse Effects

Sexual Function Effects:

• Spontaneous erections reported in males (due to MC4R activation)
• Priapism cases documented in literature
• Altered libido in both sexes

Dermatological Effects Beyond Pigmentation:

• Injection site reactions
• Darkening of existing scars
• Uneven pigmentation patterns
• Mole changes (as discussed above)

Psychiatric/Neurological:

• Fatigue and lethargy
• Facial flushing
• Dizziness
• Yawning (classical melanocortin effect)

Systemic Effects:

• Immune modulation (melanocortins affect inflammatory pathways)
• Potential hormonal effects through MC2R (though less active than other receptors)

Contamination and Quality Concerns

As an unregulated compound typically obtained through illicit markets:

• No standardized manufacturing quality controls
• Contamination with bacteria, endotoxins, or other compounds possible
• Dosage inconsistency between products
• No verification of actual content or purity
• Serious infections reported from contaminated products

Regulatory Status

Worldwide Regulatory Position

Melanotan II is NOT approved by any major regulatory agency for human use:

Regulatory Actions and Warnings

FDA Position: The U.S. Food and Drug Administration has issued warning letters to companies marketing Melanotan II products, classifying them as unapproved new drugs. The FDA has explicitly warned consumers against using these products.

European Medicines Agency: The EMA has not authorized MT-II and has warned about the risks of using unlicensed tanning products containing melanocortin analogs.

Australian TGA: The Therapeutic Goods Administration has issued multiple warnings about Melanotan products, emphasizing cancer risks and the dangers of using unregulated injectable products.

World Anti-Doping Agency: WADA has included Melanotan II on its prohibited list under the category of peptide hormones, growth factors, and related substances.

Legal Classification

The legal status of MT-II varies by jurisdiction but generally falls into one of these categories:

• Prescription medicine (requiring approval that doesn't exist)
• Unregistered/unlicensed medicine
• Prohibited substance (in sporting contexts)
• Research chemical (in limited contexts)

Difference from Melanotan I

Understanding the distinction between Melanotan II and Melanotan I (afamelanotide) is important for scientific accuracy:

Melanotan I (Afamelanotide)

Key Differences

1. Receptor Selectivity: Melanotan I is highly selective for MC1R, while MT-II activates multiple melanocortin receptors. This selectivity difference accounts for MT-I's more favorable safety profile.

2. Regulatory Status: Afamelanotide (Melanotan I, brand name Scenesse) has received regulatory approval in the European Union and Australia for treating erythropoietic protoporphyria (EPP), a rare genetic disorder causing severe photosensitivity. MT-II has no regulatory approval anywhere.

3. Side Effect Profile: MT-I's selective activity means it lacks the sexual, cardiovascular, and appetite effects associated with MC3R/MC4R activation by MT-II.

4. Clinical Development: MT-I underwent formal clinical trials and regulatory review; MT-II development was largely abandoned due to its non-selective profile and safety concerns.

5. Structure: MT-I is a linear peptide while MT-II is cyclic, contributing to their different receptor binding characteristics.

Research Limitations

Lack of Controlled Clinical Trials

The scientific understanding of Melanotan II is significantly limited by:

1. No Phase III Trials: Formal clinical development was abandoned, leaving no large-scale controlled human trials
2. Case Report Dependence: Much human safety data comes from case reports of adverse events, which cannot establish incidence rates
3. Selection Bias: Users who experience adverse effects may be more likely to seek medical attention and be documented
4. No Long-term Data: The long-term effects of MT-II use have not been systematically studied
5. Confounding Factors: Many MT-II users also engage in UV tanning, complicating attribution of effects

Publication Bias

The literature on MT-II consists largely of:

• Early preclinical pharmacology studies
• Case reports of adverse events (particularly melanoma-related)
• Surveys of illicit user populations

This creates a literature that may overrepresent certain effects while leaving other aspects poorly characterized.

Methodological Concerns

• Dosing in uncontrolled use varies widely
• Product quality in unregulated markets is unknown
• Self-reported data on effects is subject to recall and reporting biases
• Lack of control groups prevents causal inference

Areas Requiring Investigation

Should Melanotan II ever undergo formal development (which is unlikely given current alternatives), research would need to address:

• Proper dose-finding studies
• Long-term safety monitoring including dermatological surveillance
• Cardiovascular safety in controlled settings
• Carcinogenicity studies
• Drug interaction profiles

Conclusion

Melanotan II represents a cautionary example in peptide pharmacology—a compound with a clear mechanism of action and measurable biological effects that nonetheless failed to achieve therapeutic development due to significant safety concerns.

The peptide's non-selective activity at multiple melanocortin receptors produces effects extending far beyond its intended tanning application. The documented concerns regarding melanocytic nevus changes, potential melanoma associations, and cardiovascular effects have led every major regulatory agency to decline approval and issue warnings against its use.

For researchers interested in melanocortin biology, MT-II remains a pharmacological tool for understanding receptor systems. However, its use in human subjects outside properly controlled research settings cannot be recommended given:

1. Complete lack of regulatory approval worldwide
2. Documented melanoma cases and nevus changes in users
3. Cardiovascular safety concerns
4. Availability of regulated alternatives (afamelanotide) for specific medical conditions
5. Unknown long-term effects on melanocyte biology

The scientific community's understanding of melanocortin pharmacology has advanced significantly since MT-II's development, leading to more selective compounds with improved safety profiles. Melanotan II serves as a reminder that biological potency does not equate to therapeutic utility, and that receptor selectivity is often essential for safe pharmacological intervention.

References

1. Hadley ME, Dorr RT. Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Peptides. 2006;27(4):921-930. doi:10.1016/j.peptides.2005.01.029

2. Dorr RT, Ertl G, Levine N, et al. Effects of a superpotent melanotropic peptide in combination with solar UV radiation on tanning of the skin in human volunteers. Arch Dermatol. 2004;140(7):827-835. doi:10.1001/archderm.140.7.827

3. Langan EA, Ramlogan D, Panicker SP, et al. Changes in moles linked to use of unlicensed "sunless" tanning jabs. BMJ. 2009;338:b277. doi:10.1136/bmj.b277

4. Hjuler KF, Lorentzen HF. Melanoma associated with the use of melanotan-II. Dermatology. 2014;228(1):34-36. doi:10.1159/000356389

5. Reid CM, Deshpande V, McDonald KR, et al. Melanotan II: a concerning compound. Clin Exp Dermatol. 2013;38(2):196-197. doi:10.1111/j.1365-2230.2012.04462.x

6. Paurobally D, Jason J, Engelbrecht GH. Melanotan-associated melanoma in situ. Australas J Dermatol. 2012;53(4):301-302. doi:10.1111/j.1440-0960.2012.00926.x

7. Brennan R, Wells JS, Van Hout MC. The injecting use of image and performance-enhancing drugs (IPED) in the general population: a systematic review. Health Soc Care Community. 2017;25(5):1459-1531. doi:10.1111/hsc.12326

8. Ewan WE, Roberts DJ, Thomas SH. The illicit use of melanotan-I and -II in tanning. QJM. 2016;109(11):729-730. doi:10.1093/qjmed/hcw105

9. Gan EY, Tian EA, Tey HL. Management of melanocytic nevi. Am J Clin Dermatol. 2013;14(5):473-483. doi:10.1007/s40257-013-0047-4

10. Hruby VJ, Cai M, Cain JP, et al. Design of novel melanocortin receptor ligands: multiple receptors, complex pharmacology, the challenge. Eur J Pharmacol. 2011;660(1):88-93. doi:10.1016/j.ejphar.2010.10.110

11. Wessells H, Fuciarelli K, Hansen J, et al. Synthetic melanotropic peptide initiates erections in men with psychogenic erectile dysfunction: double-blind, placebo controlled crossover study. J Urol. 1998;160(2):389-393. doi:10.1016/S0022-5347(01)62903-4

12. Evans-Brown M, McVeigh J, Perkins C, Bellis MA. Human enhancement drugs: the emerging challenges to public health. North West Public Health Observatory. Liverpool John Moores University. 2012.

13. Farokhnia M, Blackford JU, Adinoff B, et al. The melanocortin system and alcohol use disorders: A systematic review of preclinical studies. Drug Alcohol Depend. 2016;163:1-11. doi:10.1016/j.drugalcdep.2016.03.001

14. Cai M, Hruby VJ. Design of cyclized selective melanotropins. Biopolymers. 2016;106(6):876-883. doi:10.1002/bip.22976

15. European Medicines Agency. Public statement on Melanotan-II: serious safety warning. EMA/499/2010. 2010.

16. Therapeutic Goods Administration. Melanotan-I and Melanotan-II: safety advisory. Australian Government Department of Health. 2011.

17. U.S. Food and Drug Administration. Warning Letters: Melanotan products. FDA Compliance Actions and Activities. 2009-2015.

18. Langendonk JG, Balwani M, Anderson KE, et al. Afamelanotide for erythropoietic protoporphyria. N Engl J Med. 2015;373(1):48-59. doi:10.1056/NEJMoa1411481

19. Lindskog Jonsson A, Rhodin S, Gjorstrup P, et al. Population-based study of self-reported adverse events associated with IPED use: a retrospective survey. Int J Drug Policy. 2018;56:168-177. doi:10.1016/j.drugpo.2018.03.020